Loading...
XKRX
084990
Market cap191mUSD
Dec 05, Last price  
6,780.00KRW
1D
0.00%
1Q
-7.50%
Jan 2017
-93.45%
IPO
-85.89%
Name

Helixmith Co Ltd

Chart & Performance

D1W1MN
XKRX:084990 chart
P/E
—
P/S
56.64
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.38%
Rev. gr., 5y
2.23%
Revenues
4.97b
+18.38%
3,888,130,9305,745,711,9307,695,186,3106,844,031,5243,157,908,5933,127,118,8004,454,515,6034,248,298,8802,316,243,8552,799,607,4744,201,622,6704,973,972,000
Net income
-15.47b
L-75.86%
-4,632,642,230265,714,850256,981,384-714,455,753-6,495,715,322-28,728,935,734-107,036,905,258-82,856,513,815-70,217,907,873-43,538,298,147-64,088,431,010-15,471,280,000
CFO
-16.72b
L-29.28%
-3,581,993,09011,221,8601,211,270,408-2,384,987,881-1,502,924,112-11,968,544,493-37,540,204,732-41,138,567,807-36,755,053,910-38,971,587,142-23,637,987,786-16,717,494,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.
URL
http://helixmith.com/
IPO date
Dec 29, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT